A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo
Name
Morandell-2013-A Reversible Gene-Ta.pdf
Size
3.67 MB
Format
Adobe PDF
Checksum (MD5)
d406c8818e5e5c22e96984b53dfdf0c8
Author(s)
Reinhardt, H. Christian
Kim, Jacob S.
Ruf, Daniela M.
Mitra, Tanya
Couvillon, Anthony D.
Yaffe, Michael B.
Cannell, Ian Gordon
Reinhardt, H. Christian
Kim, Jacob S.
Ruf, Daniela M.
Date Issued
November 2013
Journal
Cell Reports
Publisher
Elsevier
Citation
Morandell, Sandra, H. Christian Reinhardt, Ian G. Cannell, Jacob S. Kim, Daniela M. Ruf, Tanya Mitra, Anthony D. Couvillon, Tyler Jacks, and Michael B. Yaffe. “A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions Between MK2 and P53 in the DNA Damage Response In Vivo.” Cell Reports 5, no. 4 (November 2013): 868–877.
Version
Final published version
Abstract
A fundamental limitation in devising new therapeutic strategies for killing cancer cells with DNA damaging agents is the need to identify synthetic lethal interactions between tumor-specific mutations and components of the DNA damage response (DDR) in vivo. The stress-activated p38 mitogen-activated protein kinase (MAPK)/MAPKAP kinase-2 (MK2) pathway is a critical component of the DDR network in p53-deficient tumor cells in vitro. To explore the relevance of this pathway for cancer therapy in vivo, we developed a specific gene targeting strategy in which Cre-mediated recombination simultaneously creates isogenic MK2-proficient and MK2-deficient tumors within a single animal. This allows direct identification of MK2 synthetic lethality with mutations that promote tumor development or control response to genotoxic treatment. In an autochthonous model of non-small-cell lung cancer (NSCLC), we demonstrate that MK2 is responsible for resistance of p53-deficient tumors to cisplatin, indicating synthetic lethality between p53 and MK2 can successfully be exploited for enhanced sensitization of tumors to DNA-damaging chemotherapeutics in vivo.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.celrep.2013.10.025
